GENOSS Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2004-02-25
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genoss.com
Efficacy and Safety of GENOSS SES in Patients with Coronary Artery Disease
- Conditions
- Coronary Arterial Disease (CAD)
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1116
- Registration Number
- NCT06841510
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Safety and Effectiveness of GENOSS DES in Patients With Multivessel Coronary Artery Disease
- Conditions
- Percutaneous Coronary InterventionMultivessel Coronary Artery Disease
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06168305
- Locations
- 🇰🇷
Korea University GURO Hospital, Seoul, Korea, Republic of
Evaluation of Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent
- Conditions
- Coronary Artery DiseasePercutaneous Coronary Intervention
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06086496
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure
- Conditions
- Coronary Artery DiseasePercutaneous Coronary InterventionDual Antiplatelet Therapy
- Interventions
- Device: Genoss DES stent
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06075433
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wŏnju, Gangwon state, Korea, Republic of
Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease
- Conditions
- Percutaneous Coronary InterventionDual Antiplatelet Therapy
- Interventions
- Device: Genoss DES stent
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06075420
- Locations
- 🇰🇷
Wonju Severance Christian Hospital, Wonju, Gangwon state, Korea, Republic of
Efficacy and Safety of GENOSS® SES in Patients with Acute Coronary Syndrome (GENOSS ACS)
- Conditions
- Percutaneous Coronary InterventionAcute Coronary Syndrome
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 757
- Registration Number
- NCT06075368
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Efficacy and Safety of GENOSS® DES in Patients with Coronary Artery Disease
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1022
- Registration Number
- NCT06066476
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis
- Conditions
- Drug-eluting StentCoronary Artery Disease
- Interventions
- Device: Genoss® DES system, Genoss® Osfit system
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06066450
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
Compare the Effectiveness and Safety of Genoss® DCB and IN.PACT Admiral® DCB in Patients With Peripheral Artery Disease
- Conditions
- Peripheral Artery DiseaseDe Novo Stenosis
- Interventions
- Device: IN.PACT Admiral® DCBDevice: Genoss® DCB
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 119
- Registration Number
- NCT05134545
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
- Conditions
- Coronary Artery Disease
- Interventions
- Device: GENOSS® DCBDevice: SeQuent® Please NEO
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 204
- Registration Number
- NCT05096442
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of